{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T14:16:30Z","timestamp":1772720190923,"version":"3.50.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T00:00:00Z","timestamp":1700524800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T00:00:00Z","timestamp":1700524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Institute of Chronic Illnesses, Inc, United States"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biometals"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Environmental mercury exposure possesses a significant risk to many human populations. At present there are no effective treatments for acute mercury toxicity. A new compound, N,N\u2032bis-(2-mercaptoethyl) isophthalamide (NBMI), a lipophilic chelating agent was created to tightly\/irreversibly bind mercury. A post hoc dose-dependent analysis of NBMI therapy was undertaken on data from a randomized controlled NBMI human treatment trial on 36 Ecuadorian gold miners with elevated urinary mercury concentrations. Study subjects were randomly assigned to receive 100 milligram (mg) NBMI\/day, 300\u00a0mg NBMI\/day, or placebo for 14 days. For each study subject daily mg NBMI dose\/Kilogram (Kg) bodyweight were determined and plasma and urine mercury concentrations (micrograms (\u00b5g)\/Liter (L)) on study day 1 (pre-NBMI treatment), 15 (after 14 days of NBMI treatment) and 45 (30 days after NBMI treatment) were correlated with NBMI dosing using the linear regression statistic in SAS. Regression revealed significant inverse correlations between increasing per mg NBMI\/Kg bodyweight\/day and reduced concentrations of urinary and plasma mercury on study day 15 (reduced by in urine\u2009=\u200918\u201320\u00a0\u00b5g\/L and plasma\u2009=\u20092\u00a0\u00b5g\/L) and study day 30 (reduced by in urine\u2009=\u200915\u201320\u00a0\u00b5g\/L and plasma\u2009=\u20094\u00a0\u00b5g\/L) and significant correlations between reductions in mercury concentrations in urine and plasma. Significant 30% reductions in urinary mercury concentrations per mg NBMI\/Kg bodyweight\/day administered for 14 days were observed. This study supports the dose-dependent ability of NBMI therapy to significantly reduce mercury concentrations, particularly in the urine, in an acutely mercury exposed human population. NBMI therapy should be evaluated in other mercury exposed populations.<\/jats:p>","DOI":"10.1007\/s10534-023-00560-3","type":"journal-article","created":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T10:04:17Z","timestamp":1700561057000},"page":"433-445","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Reductions in plasma and urine mercury concentrations following N,N\u2032bis-(2-mercaptoethyl) isophthalamide (NBMI) therapy: a post hoc analysis of data from a randomized human clinical trial"],"prefix":"10.1007","volume":"37","author":[{"given":"David A.","family":"Geier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark R.","family":"Geier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,21]]},"reference":[{"key":"560_CR1","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1080\/02772248.2012.657199","volume":"94","author":"D Clarke","year":"2012","unstructured":"Clarke D, Buchanan R, Gupta N, Haley B (2012) Amelioration of acute mercury toxicity by a novel, non-toxic lipid soluble chelator N,N\u2032bis-(2-mercaptoethyl)isophthalamide: effect on animal survival, health, mercury excretion, and organ accumulation. Toxicol Environ Chem 94:616\u2013640. https:\/\/doi.org\/10.1080\/02772248.2012.657199","journal-title":"Toxicol Environ Chem"},{"key":"560_CR2","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/reel.12079","volume":"23","author":"HH Eriksen","year":"2014","unstructured":"Eriksen HH, Perrez FX (2014) The minimata convention: a comprehensive response to a global problem. Rev Eur Comm Int Environ Law 23:195\u2013209. https:\/\/doi.org\/10.1111\/reel.12079","journal-title":"Rev Eur Comm Int Environ Law"},{"key":"560_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph7072745","volume":"7","author":"SJS Flora","year":"2010","unstructured":"Flora SJS, Pachauri V (2010) Chelation in metal intoxication. Int J Environ Res Public Health 7:2745. https:\/\/doi.org\/10.3390\/ijerph7072745","journal-title":"Int J Environ Res Public Health"},{"key":"560_CR4","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/JAC.0000000000000135","volume":"39","author":"RL Fuller","year":"2016","unstructured":"Fuller RL, Averill RF, Muldoon JH, Hughes JS (2016) Comparison of the properties of regression and categorical risk-adjustment models. J Ambul Care Manag 39:157\u2013165. https:\/\/doi.org\/10.1097\/JAC.0000000000000135","journal-title":"J Ambul Care Manag"},{"key":"560_CR5","doi-asserted-by":"publisher","first-page":"960327122110634","DOI":"10.1177\/09603271221106341","volume":"41","author":"DA Geier","year":"2022","unstructured":"Geier DA, Geier MR (2022) Dental amalgam fillings and mercury vapor safety limits in American adults. Hum Exp Toxicol 41:9603271221106340. https:\/\/doi.org\/10.1177\/09603271221106341","journal-title":"Hum Exp Toxicol"},{"key":"560_CR6","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1021\/tx049904e","volume":"17","author":"GN George","year":"2004","unstructured":"George GN, Prince RC, Gailer J, Buttigieg GA, Denton MB, Harris HH, Pickering IJ (2004) Mercury binding to the chelation therapy agents DMSA and DMPS and the rational design of custom chelators for mercury. Chem Res Toxicol 17:999\u20131006. https:\/\/doi.org\/10.1021\/tx049904e","journal-title":"Chem Res Toxicol"},{"key":"560_CR7","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.toxrep.2020.07.012","volume":"38","author":"T Ke","year":"2020","unstructured":"Ke T, Bornhorst J, Scherdtle T, Santamaria A, Bowman AB, Skalny AV, Aschner M (2020) Therapeutic efficacy of the N,N\u2032bis-(2-mercaptoethyl) isophthalamide chelator for methylmercury intoxication in Caenorhabditis elegans. Neurotox Res 38:133\u2013144. https:\/\/doi.org\/10.1016\/j.toxrep.2020.07.012","journal-title":"Neurotox Res"},{"key":"560_CR8","first-page":"914","volume":"10","author":"KV Mann","year":"1991","unstructured":"Mann KV, Travers JD (1991) Succimer, an oral lead chelator. Clin Pharm 10:914\u2013922","journal-title":"Clin Pharm"},{"key":"560_CR9","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12940-018-0358-1","volume":"17","author":"P Schutzmeier","year":"2018","unstructured":"Schutzmeier P, Baquerizo AF, Castillo-Tandazo W, Focil N, Bose-O\u2019Reily S (2018) Efficacy of N,N\u2032bis-(2-mercaptoethyl) isophthalamide on mercury intoxication: a randomized controlled trial. Environ Health 17:15. https:\/\/doi.org\/10.1186\/s12940-018-0358-1","journal-title":"Environ Health"},{"issue":"9","key":"560_CR10","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1021\/tx3001847","volume":"25","author":"RK Zalups","year":"2012","unstructured":"Zalups RK, Bridges CC (2012) Relationships between the renal handling of DMPS and DMSA and the renal handling of mercury. Chem Res Toxicol 25(9):1825\u20131838. https:\/\/doi.org\/10.1021\/tx3001847","journal-title":"Chem Res Toxicol"},{"key":"560_CR11","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1021\/ic0607639","volume":"46","author":"KM Zaman","year":"2007","unstructured":"Zaman KM, Blue LY, Huggins FE, Atwood DA (2007) Cd, hg and pb compounds of benzene-1,3-diamidoethanethiol(BDETH2). Inorg Chem 46:1975\u20131980. https:\/\/doi.org\/10.1021\/ic0607639","journal-title":"Inorg Chem"}],"container-title":["BioMetals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10534-023-00560-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10534-023-00560-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10534-023-00560-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T08:07:26Z","timestamp":1712736446000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10534-023-00560-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,21]]},"references-count":11,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["560"],"URL":"https:\/\/doi.org\/10.1007\/s10534-023-00560-3","relation":{},"ISSN":["0966-0844","1572-8773"],"issn-type":[{"value":"0966-0844","type":"print"},{"value":"1572-8773","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,21]]},"assertion":[{"value":"12 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mr. David Geier and Dr. Mark Geier are are small shareholders in EmeraMed, Ltd, which is developing NBMI as treatment for mercury toxicity.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}